Triple-negative breast cancer—current status and future directions
Oleg Gluz(Women‘s Healthcare Group), Nadia Harbeck(Breast Center), Ulrike Nitz(Women‘s Healthcare Group), Lajos Pusztai(Yale University), Nina Gottschalk, C Liedtke(Klinik für Frauenheilkunde)
Cited by 692
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Breast cancer
|The Lancet|2016|2.3k